• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当前欧洲心血管疾病管理指南:近半数人口的医疗治疗现实吗?

Current European guidelines for management of cardiovascular disease: Is medical treatment in nearly half a population realistic?

机构信息

1 National Institute of Public Health, University of Southern Denmark, Denmark.

2 Research Centre for Prevention and Health, Rigshospitalet, Glostrup, Denmark.

出版信息

Eur J Prev Cardiol. 2018 Jan;25(2):157-163. doi: 10.1177/2047487317738826. Epub 2017 Nov 2.

DOI:10.1177/2047487317738826
PMID:29095052
Abstract

Background Health checks of the general population are widely used to prevent cardiovascular diseases, but are the current clinical guidelines from the European Society of Cardiology (ESC) suitable for screening the general population? Design A cross-sectional, population-based study of 978 men and women aged 40-65 years examined in 2010-2011 was used to estimate the proportion of the general Danish population fulfilling the criteria from the clinical guidelines from the ESC on medical treatment and lifestyle intervention to prevent cardiovascular disease. Methods The ESC criteria for medical treatment and lifestyle intervention were applied to a general population using information on previous cardiovascular diseases, known diabetes, urinalbumin, smoking, total cholesterol, systolic and diabolic blood pressure, low-density lipoprotein cholesterol and a multifactor risk score (SCORE). Results A total of 12.5% fulfilled the criteria for immediate medical treatment to prevent cardiovascular diseases. Furthermore, 30.4% are recommended for medical treatment if an initial lifestyle intervention fails summing to 42.9% eligible for medical treatment. The majority (79%) of persons aged 60-65 years are eligible for medical treatment, while close to half (44.9%) of all persons aged 50-59 years are recommended for medical treatment. Conclusion If ESC's guidelines were followed in Denmark, a conservative estimate shows that medical preventive treatment would involve nearly half the general population aged 40-65 years. The use of these guidelines in screening of the general population can be questioned as realistic and suitable.

摘要

背景

人群健康检查被广泛用于预防心血管疾病,但欧洲心脏病学会 (ESC) 的现行临床指南是否适合对普通人群进行筛查?

设计

一项 2010-2011 年对 978 名 40-65 岁男女进行的横断面、基于人群的研究用于估计符合 ESC 关于预防心血管疾病的药物治疗和生活方式干预的临床指南标准的丹麦普通人群的比例。

方法

使用先前的心血管疾病、已知糖尿病、尿白蛋白、吸烟、总胆固醇、收缩压和舒张压、低密度脂蛋白胆固醇和多因素风险评分 (SCORE) 的信息,将 ESC 药物治疗和生活方式干预的标准应用于普通人群。

结果

共有 12.5%的人符合立即进行心血管疾病预防治疗的标准。此外,如果初始生活方式干预失败,有 30.4%的人建议进行药物治疗,这加起来有 42.9%的人有资格进行药物治疗。大多数(79%)60-65 岁的人有资格进行药物治疗,而近一半(44.9%)50-59 岁的人建议进行药物治疗。

结论

如果丹麦遵循 ESC 的指南,保守估计有近一半的 40-65 岁普通人群将接受药物预防治疗。这些指南在普通人群筛查中的使用是否合理和合适值得质疑。

相似文献

1
Current European guidelines for management of cardiovascular disease: Is medical treatment in nearly half a population realistic?当前欧洲心血管疾病管理指南:近半数人口的医疗治疗现实吗?
Eur J Prev Cardiol. 2018 Jan;25(2):157-163. doi: 10.1177/2047487317738826. Epub 2017 Nov 2.
2
Editor's Presentation.编辑致辞。
Eur J Prev Cardiol. 2018 Jan;25(2):115-117. doi: 10.1177/2047487317750306.
3
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.27 个国家的冠心病患者生活方式及对心血管危险因素控制的影响:欧洲心脏病学会 ESC-EORP EUROASPIRE V 注册研究结果。
Eur J Prev Cardiol. 2019 May;26(8):824-835. doi: 10.1177/2047487318825350. Epub 2019 Feb 10.
4
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.欧洲动脉粥样硬化调查项目IV:欧洲心脏病学会对来自24个欧洲国家的冠心病患者的生活方式、危险因素及治疗管理情况的调查。
Eur J Prev Cardiol. 2016 Apr;23(6):636-48. doi: 10.1177/2047487315569401. Epub 2015 Feb 16.
5
Guideline implementation in a multicenter study with an estimated 44% relative cardiovascular event risk reduction.在一项多中心研究中实施指南,估计心血管事件相对风险降低44%。
Clin Cardiol. 2003 May;26(5):243-9. doi: 10.1002/clc.4960260510.
6
Translating guidelines to practice: findings from a multidisciplinary preventive cardiology programme in the west of Ireland.将指南转化为实践:爱尔兰西部多学科预防心脏病学项目的研究结果
Eur J Prev Cardiol. 2014 Mar;21(3):366-76. doi: 10.1177/2047487313498831. Epub 2013 Jul 24.
7
Getting patients to target- implementing the guidelines.让患者达标——实施指南。
Curr Vasc Pharmacol. 2012 Nov;10(6):715-7. doi: 10.2174/157016112803520701.
8
Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.美国心脏病学会/美国心脏协会(ACC/AHA)胆固醇指南对几种美国社区卫生中心网络中糖尿病患者心血管疾病预防中他汀类药物未充分利用的影响。
J Am Heart Assoc. 2017 Jul 3;6(7):e005627. doi: 10.1161/JAHA.117.005627.
9
Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions.心血管疾病高危人群的生活方式与风险因素管理。欧洲心脏病学会关于欧洲通过干预进行二级和一级预防以减少事件行动(EUROASPIRE)IV在14个欧洲地区开展的横断面调查的报告。
Eur J Prev Cardiol. 2016 Dec;23(18):2007-2018. doi: 10.1177/2047487316667784. Epub 2016 Sep 27.
10
Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study.一般人群中心血管病药物预防措施的依从性:初级保健多学科干预(IMAP)研究。
Eur J Prev Cardiol. 2012 Oct;19(5):1074-81. doi: 10.1177/1741826711418166. Epub 2011 Aug 2.

引用本文的文献

1
Biomarkers in Cardiovascular Disease: The Dilemma of Racial Differences.心血管疾病中的生物标志物:种族差异的困境。
J Am Heart Assoc. 2019 Sep 17;8(18):e014295. doi: 10.1161/JAHA.119.014295. Epub 2019 Sep 13.
2
A data-zone scoring system to assess the generalizability of clinical trial results to individual patients.一种数据分区评分系统,用于评估临床试验结果对个体患者的可推广性。
Eur J Prev Cardiol. 2019 Apr;26(6):569-575. doi: 10.1177/2047487318815967. Epub 2018 Nov 26.